dc.contributor.author |
Masebe, Tracy |
|
dc.contributor.author |
Bessong, Obong Pascal |
|
dc.contributor.author |
Ndip, Roland Ndip |
|
dc.contributor.author |
Meyer, Debra |
|
dc.date.accessioned |
2016-10-30T08:33:51Z |
|
dc.date.available |
2016-10-30T08:33:51Z |
|
dc.date.issued |
2014-06-26 |
|
dc.identifier.issn |
1422-0067 |
|
dc.identifier.other |
doi: 10.3390/ijms150711403 |
|
dc.identifier.uri |
http://hdl.handle.net/11602/658 |
|
dc.description |
Publication of this article was funded by the Universiry of Venda: HIV/AIDS & Global Health Research Programme, Department of Microbiology |
en_US |
dc.description |
CITATION: Masebe Tracy et al. (2014): Genetic variants of APOC3 Promoter and HLA-B Genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study, International Journal of Molecular Sciences, 15,11403-11415; doi.: 10.3390/ijms157111403. |
|
dc.description.abstract |
Metabolic disorders and hypersensitivities affect tolerability and impact
adherence to highly active antiretroviral therapy (HAART). The aim of this study was to
determine the prevalence of C-482T/T-455C variants in the Apolipoprotein C3 (APOC3)
promoter gene and Human leukocyte antigen (HLA)-B*57:01, known to impact lipid
metabolic disorders and hypersensitivity respectively; and to correlate genotypes with
gender, CD4+ cell count and viral load in an HIV infected cohort in northern South Africa.
Frequencies of C-482 and T-455 polymorphisms in APOC3 were determined by restriction
fragment length polymorphism analysis. Allele determination for HLA-B was performed
with Assign SBT software in an HLA library. Analysis of APOC3 C-482 site revealed a
prevalence of 196/199 (98.5%) for CC, 1/199 (0.5%) for CT and 2/199 (1.0%) for TT
genotype (p = 0.000 with 1° of freedom; χ2 = 126.551). For the T-455 site, prevalences
were: 69/199 (35%) for TT and 130/199 (65%) for the CC genotype (p = 0.000 with 1° of
freedom; χ2 = 199). There was no association between gender and the presence of −482
(p = 1; χ2 = 0.00001) or −455 genotypes (p = 0.1628; χ2 = 1.9842). There was no significant
difference in the increase in CD4+ cell count irrespective of genotypes. Significant
increases in CD4+ cell count were observed in males and females considering the −455C
OPEN ACCESS
Int. J. Mol. Sci. 2014, 15 11404
genotype, but not in males for the −455T genotype. Viral load decreases were significant
with the −455C and −482C genotypes irrespective of gender. HLA-B*57:01 was not
identified in the study cohort. The apparently high prevalence of APOC3 T-455CC
genotype needs confirmation with a larger samples size and triglyceride measurements to
support screening of patients to pre-empt HAART associated lipid disorders. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Molecular Diversity Preservation International (MDPI) |
en_US |
dc.subject |
Genetic variants |
en_US |
dc.subject |
APOC3 |
en_US |
dc.subject |
HLA-B |
en_US |
dc.subject |
Highly active antiretroviral therapy |
en_US |
dc.subject |
Lipid disorders |
en_US |
dc.subject |
South Africa |
en_US |
dc.title |
Genetic Variants of APOC3 Promoter and HLA-B genes in an HIV Infected Cohort in Northern South Africa: A Pilot Study |
en_US |